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BACKGROUND: Cancer is a multifactorial disease com-
posed of cells that show somatic mutations and epige-
netic changes. The aim of this study was to investigate
the expression of proteins involved in the development
and maintenance of epithelia, cell cycle regulation, and
apoptosis in human oral squamous cell carcinoma
(OSCC) tissue samples.
METHODS: A tissue microarray containing 65 primary
human OSCC specimens was immunolabeled for bcl-2,
survivin, epidermal growth factor receptor (EGFR), p21,
p53, p63, and cleaved caspase-3.
RESULTS: Samples were scored for percentage of posi-
tively stained tumor cells and staining intensity. A total
immunostaining score was also calculated, using the
product of percentage and intensity scores. All speci-
mens showed high scores, > 75%, for p63 and survivin,
and 75.4% of the specimens also presented high EGFR
expression. All cases showed p53-positive cells. p21
showed a diffuse staining pattern. The percentage of
cells positive for cleaved caspase-3 and bcl-2 was low.
CONCLUSIONS: The high frequency of tumor cells
expressing p63 and survivin highlights the role of these
proteins in the malignant transformation of oral epithe-
lium. Collectively, our results suggest that p63 and sur-
vivin may constitute attractive targets for cancer
therapy in patients with OSCC.
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Introduction
Cancer is recognized as a multifactorial disease composed
of cells that show somatic mutations and epigenetic
changes (Grizzi et al, 2006). Oral cancer is a subgroup of
head and neck cancers; it is the sixth most frequent type
of cancer in the general population, with variable inci-
dence rates across countries (Laimer et al, 2007). Despite
advances in modern technologies, the 5-year relative sur-
vival rate of patients with oral cavity and pharynx cancer
has shown only a modest improvement over the past few
years (van der Waal, 2013).
At the individual level, the TNM classiﬁcation does not
reliably predict clinical outcomes or the histological grad-
ing of oral cancer in general and of oral squamous cell
carcinomas (OSCC) in particular (Keski-S€antti et al,
2007). The relationship among key regulatory proteins of
survival/death pathways and their differentiation may
potentially have diagnostic and therapeutic value in
OSCC.
The p63 protein is a transcription factor involved in
epidermal development and maintenance (Candi et al,
2006). Its overexpression is associated with tumors known
to harbor a high frequency of p53 mutations (Mirzayans
et al, 2012). From an evolutionary perspective, the TP53
family comprises three members (TP53, TP63, TP73),
probably deriving from the triplication of one ancestral
gene (Hibi et al, 2000; Yang et al, 2002). The p53 tran-
scription factor also plays a role in DNA damage. Simi-
larly to protein p63, p53 can participate in both apoptosis
and cell proliferation events (Yang et al, 1999; Hibi et al,
2000; Little and Jochemsen, 2002; Candi et al, 2008; van
der Vorst et al, 2012).
The p21WAF1 protein is a cyclin-dependent kinase inhib-
itor essential for the regulation of cell proliferation, differ-
entiation, and apoptosis. The expression of p21 itself is
regulated by p53, leading to either inhibition of cell cycle
progression or apoptosis (Gomes et al, 2008; Mirzayans
et al, 2012). p21 is also a substrate for caspase-3, a medi-
ator of the intrinsic cell death pathway, able to activate
mechanisms that prevent cell death via cleavage of classi-
cal caspase-3 (Warfel and El-Deiry, 2013). Caspases are
modulated by several endogenous cellular factors, includ-
ing inhibitor of apoptosis proteins (IAPs) (Burz et al,
2009). Survivin is an IAP and controls cell division by
regulating mitotic activity at different levels. Upregulation
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of survivin has been detected at the protein level in
OSCCs (De Maria et al, 2009).
Bcl-2 acts as a key regulator of cell proliferation, differ-
entiation, and survival. It is an anti-apoptotic protein that
shows a high expression in several tumors (Nemeth et al,
2005).
Finally, epidermal growth factor receptor (EGFR) is
involved in various cellular processes, including cell
growth, motility, and invasion, angiogenesis, inhibition of
apoptosis, and cell adhesion. EGFR may enhance the
malignant potential of epithelial tissues via overexpres-
sion (Herbst, 2004; Katz et al, 2007; Laimer et al,
2007).
While most of these proteins have been studied individ-
ually in the context of oral cancer, their expression pat-
terns have not been determined globally in human
OSCCs. The aim of this study was the analysis of the
expression of these proteins in a tissue microarray (TMA)
containing 65 primary human OSCC specimens.
Materials and methods
This study protocol was reviewed and approved by the
Institutional Review Board of the institution where the
study was carried out. Informed consent was obtained
from all participants before sample collection.
TMA preparation
The tissue microarrays were prepared using incisional
biopsies of 65 patients with primary OSCC. None of the
patients had undergone radiotherapy or chemotherapy
prior to surgery. Data on age, gender, and lesion site are
summarized in Table 1. Samples were formalin ﬁxed and
parafﬁn embedded. Hematoxylin and eosin-stained slides
from each specimen were assessed by an experienced oral
pathologist. Two tissue cylinders of 1-mm diameter, suit-
able for inclusion in the TMA, were punched from
selected areas of each donor block and brought into a reci-
pient block. Four samples had two donor blocks and one
had three donor blocks. An automated tissue arrayer
(ATA-27, Beecher Instruments Inc., Sun Prairie, WI,
USA), from the Human Tissue Resource Center of the
University of Chicago, was used to make the recipient
block. One recipient block was made, containing 142
OSCC cores and human samples for use as positive con-
trol cores (breast cancer, tonsil, lung cancer, and placenta
tissues).
Immunohistochemistry
Four-lm thick sections were deparafﬁnized and rehydrat-
ed through ethanol. Antigen retrieval was performed, and
sections were incubated with primary antibodies for bcl-2
(clone E17, Epitomics, 1:50), survivin (clone D8, Santa
Cruz Biotechnology, 1:50), EGFR (clone 31G7, Zymed,
1:100), p21WAF1/Cpi1 (clone SX118, Dako, 1:25), p53
(clone DO-1, Calbiochem, 1:100), p63 [clone
4A4 + Y4A3(63PO2), Neomarkers 1:100], and cleaved
caspase-3 (clone Asp 175, 5ª1, Cell Signaling, 1:50), for
1 h at room temperature. The EnVisionTM+ system
(Dako, Carpinteria, CA, USA) and 3, 3-diamino benzi-
dine (Dako, Carpinteria, CA, USA) were used for visual-
ization. For each core, images (4009 magniﬁcation)
from all contiguous and consecutive ﬁelds were captured
using a video camera (Q-Color5TM, Olympus America,
Inc., Center Valley, PA, USA) coupled to a microscope.
Images were recorded using the QCapture ProTM 5 soft-
ware (QImaging Co., Surrey, BC, Canada). A separate
ﬁle was created for each immunolabel, and all images of
the same core were stored in a subﬁle. Immunolabeled
tumor cells were scored according to percentage of the
total number of cells and graded semiquantitatively, as
follows: 0% = 0, <25% = 1, 25–75% = 2, >75% = 3.
Staining intensity was also evaluated semiquantitatively
and was graded as follows: negative, grade 0; mild,
grade +1; moderate, grade +2; and high staining inten-
sity, grade +3. Finally, a total immunostaining score was
calculated, using the product of percentage and intensity
scores (the total score could range from 0 to 9). Tumors
were randomly categorized into samples with high, low,
and no expression, using the following cut-off values:
0 = no expression, 1–3 = low, and 4–9 = high expres-
sion. The immunolabeling area (nucleus, cytoplasm, or
membrane, alone or combined) was observed and
recorded. Slides were assessed by three oral pathologists
(M.G.O., P.V.R., M.S.F.) previously calibrated, with
acceptable intra-observer and interobserver kappa values
(0.7–1.0).
Statistical analysis
The Friedman non-parametric test, followed by the multi-
ple comparison test, was used to analyze the total scores
obtained for staining intensity vs. percentage of positive
cells in the different immunolabels. Spearman’s correlation
coefﬁcient was used to assess correlations between stain-
ing intensity scores and percentage of positive cells. Sixty-
one samples had at least one score for each of the seven
immunolabels and were considered suitable for analysis.
Intensity and positivity scores obtained for each immu-
nolabel were analyzed in relation to patient gender using
the Mann–Whitney non-parametric test, and in relation to
patient age and lesion site using the Kruskal–Wallis non-
parametric test. For all analyses, P < 0.05 was considered
statistically signiﬁcant.
Table 1 Patient characteristics
n %
Gender
Male 09 13.85
Female 56 86.15
Age (years)
≤50 16 24.6
51–60 23 35.4
61–90 21 32.3
NI 05 7.7
Lesion site
Palate 05 7.7
Lower lip 06 9.23
Tongue 13 20
Floor of the mouth 20 30.77
Gingiva 21 32.31
NI, not informed.
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Results
The analysis of patient characteristics revealed no signiﬁ-
cant differences in staining intensity scores and percentage
of positive cells in relation to patient age and lesion site
for all proteins investigated (data not shown). No gender
differences were observed for staining intensity either.
However, when analyzing percentage of positive cells,
males showed signiﬁcantly higher scores for p21 than
females (male, mean rank: 31.35; female, mean rank:
17.94; P = 0.035).
Figure 1 shows the total scores calculated for staining
intensity vs. percentage of positive cells in each immunola-
bel. All specimens showed high p63 expression, >75%, and
most of them displayed p63 positivity with gradual
decreases from the basal layer toward the squamous layer.
All specimens also showed high survivin expression, >75%,
with most labeled cells located in the nucleus/cytoplasm.
No relationship was observed between a large number of
labeled cells and poorly differentiated carcinomas.
Forty-nine specimens (75.4%) showed high EGFR
expression, predominantly located in the membrane and
membrane/cytoplasm. Finally, all biopsies showed either
low or high scores for p53, with 73.8% (n = 48) of the
cases showing high p53 labeling. The p53 protein revealed
a predominantly nuclear and nuclear/cytoplasmic localiza-
tion, and immunolabeled cells displayed a diffuse pattern.
Higher numbers of labeled cells were observed in the
most poorly differentiated carcinomas.
Neoplasms with keratin pearls were p63-, EGFR-, p53-,
and survivin-positive only in their peripheral region. All
samples analyzed for p21 expression showed a diffuse
staining pattern. Cleaved caspase-3 and bcl-2 were the
proteins with the lowest numbers of stained cells when
compared with the other proteins investigated.
Spearman’s correlation coefﬁcient for percentage inter-
vals, considering samples with at least one score for each
immunolabel, revealed a negative correlation between p53
and cleaved caspase-3 and a positive correlation between
p21 and p63 (Table 2).
Discussion
In this sample, all specimens showed high levels of p63
and survivin expression, suggesting an involvement of
these two proteins in the development and maintenance of
oral cancer.
The p63 protein had already been shown to be involved
in epithelial development by regulating stem cell/transient
amplifying cells, their differentiation, and cell death (Yang
et al, 1999; Little and Jochemsen, 2002; Candi et al,
2006). p63 encodes at least six isoforms, divided in two
groups: TAp63, involved in apoptosis, and ΔNp63,
involved in cell proliferation (Yang et al, 1999, 2002; Lit-
tle and Jochemsen, 2002; Gurgel et al, 2008). Our results
corroborate previous ﬁndings regarding the role played by
this protein in the regulation of epithelial differentiation
(Gurgel et al, 2008; Rosenbluth et al, 2009): in our sam-
ple of OSCC specimens, p63 was found in all epithelial
layers, with gradual decreases from the basal toward the
squamous layer.
Survivin has also been detected in the cytoplasm and
nucleus of cancer cells (Qi et al, 2010), in line with our
ﬁndings. Cytoplasmic survivin has been characterized as
anti-apoptotic and associated with microtubules, directly
or indirectly interfering with the function of caspases;
nuclear survivin, in turn, is suspected to control cell divi-
sion (Qi et al, 2010).
The proteins assessed in the present study, namely
p63, p53, p21, survivin, bcl-2, and EGFR, are directly
involved in the inhibition or induction of apoptosis.
Immunolabeling of cleaved caspase-3 suggests that an
apoptotic event has occurred. Based on our ﬁndings and
on relevant literature, we hypothesize that, in our sample,
p21 and survivin downregulated apoptosis, inﬂuenced by
p63 and p53.
Abnormal accumulation of p53 is a common ﬁnding in
the development of oral carcinomas (Bidaud et al, 2010).
Mutations in the TP53 gene are the abnormalities most
frequently found in OSCCs. Notwithstanding, most of
these mutations result in gains of function, including the
ability to interact with mitochondrial caspase-3, establish-
ing an apoptosis-resistant phenotype (Mirzayans et al,
2012). We believe that this mechanism could explain, at
least in part, the negative correlation observed between
p53 and cleaved caspase-3.
To block the cell cycle, p53 induces transcription of the
p21WAF1 protein. Furthermore, when p21WAF1 binds to
PCNA, it directly inhibits DNA replication during the S
phase (Whyte et al, 2002). Finally, p21WAF1 immunola-
beling is altered during oral carcinogenesis, increasing as
the severity of histological ﬁndings progresses (Weinberg
and Denning, 2002; Choi et al, 2003; Warfel and
El-Deiry, 2013).
Our results show a signiﬁcant direct correlation between
p63 and p21, which may be explained by a p53-indepen-
dent induction of p21WAF1 in response to cell differentia-
tion signals – it should be noted that p21 also has a role
in maintaining stem cell quiescence, acting as an oncogene
(Patel et al, 2009; Warfel and El-Deiry, 2013).
Another gene that may be induced by gain-of-function
mutations in p53 proteins is EGFR. In our study, two
specimens (3.1%) failed to show EGFR expression, and
75.4% of the samples showed highly stained tumor cells,
a result similar to that reported by Laimer et al (2007),
Monteiro et al (2010).
Figure 1 Total scores for percentage vs. intensity of stained tumor cells.
Cut-off values: 0 = no expression; 1–3 = low; 4–9 = high expression
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Functional dissection of the bcl-2 family reveals pro-
teins with primary anti-apoptotic (bcl-2, bcl-xl, bcl-w, and
Mcl-1, among others) vs. pro-apoptotic (Bax, Bak, Bad,
Bok, and Bid, among others) roles (Mallick et al, 2009;
Patel et al, 2009). The anti-bcl-2 antibody used in our
study does not cross-react with other bcl-2 protein family
members. Differently from various malignant lesions that
show a high percentage of bcl-2-positive cells (Patel et al,
2009), 95.4% of our specimens did not show bcl-2 immu-
nopositivity. We speculate that many of the studies show-
ing high bcl-2 immunolabeling in OSCCs may have used
antibodies that cross-react with other members of this fam-
ily. Our results revealed a higher percentage of cleaved
caspase-3 than of bcl-2 immunolabeling, and none of the
three bcl-2-positive samples was positive for cleaved cas-
pase-3. These results lead to the hypothesis that, in this
sample, the anti-apoptotic bcl-2 protein may not have par-
ticipated in the pathway that suppresses apoptosis in tumor
cells – again, it should be noted that another property of
mutated p53 is to downregulate the transcription of some
genes, including those that encode bcl-2 (Mirzayans et al,
2012).
Previous studies (Putti et al, 2002; Choi et al, 2003;
Tanaka et al, 2003; Bascones et al, 2005; Kummoona et al,
2007; Bidaud et al, 2010) were the basis for the immuno-
histochemistry pattern of the proteins investigated in normal
mucosa epithelium. Non-neoplastic tissues adjacent to
tumors were not included in this study because they could
present abnormalities regardless of their morphology. Our
belief is based on the ﬁeld cancerization theory proposed by
Slaughter et al (1953) and widely studied until today.
As shown in the present study, immunohistochemistry
provides valuable information that can guide treatment
decisions in the management of cancer patients (Figure 2).
Collectively, our ﬁndings highlight the role played by p63
and survivin in the malignant transformation of oral epi-
thelium and indicate that they could be attractive targets
for cancer therapy in patients with OSCC.
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